Emerson Automation Solutions, Durham, NC- USA
BioPhorum, The Gridiron Building, 1 Pancras Square, London, NIC 4AG UK
International Society for Pharmaceutical Engineering (ISPE), 6110 Executive Blvd, North Bethesda, MD 20852, USA
MESA International, 1800E.Ray Road, STE A106, Chandler, AZ 85225 USA
Email: Shri.harshal@gmail.com
The life sciences industry operates under stringent regulatory frameworks to ensure patient safety, product quality, and data integrity across drug development, manufacturing, and distribution. Compliance with standards such as Good Manufacturing Practices (GMP), 21 CFR Part 11, and ISO 13485 presents multifaceted challenges, including complex documentation requirements, rigorous process validation, and the need for real-time oversight. These demands often strain operational resources, increase costs, and risk non-compliance penalties. This paper investigates the transformative role of Manufacturing Execution Systems (MES) and advanced batch processing methodologies in addressing these challenges. The study's objectives are to explore MES capabilities that facilitate compliance management, evaluate their impact on operational efficiency and error reduction, and propose actionable strategies for integrating MES into existing manufacturing infrastructures without disrupting established workflows. The research employs a qualitative methodology, combining a systematic review of industry practices, case studies from pharmaceutical and biotechnology firms, and analysis of regulatory frameworks. Key MES functionalities such as real-time data capture, Electronic Batch Records (EBRs), automated audit trails, and deviation tracking are identified as critical enablers of compliance. These tools ensure traceability, enhance data integrity, and provide regulators with verifiable records, thereby simplifying audits and inspections. The study also examines how MES integrates with Enterprise Resource Planning (ERP) systems and Quality Management Systems (QMS) to create a cohesive compliance ecosystem. Results demonstrate that MES implementation significantly reduces manual errors, accelerates batch release cycles, and improves reporting accuracy, leading to measurable gains in operational efficiency. Furthermore, MES-driven automation minimizes compliance-related downtime and mitigates risks associated with human intervention in regulated processes. The paper proposes a phased integration framework for MES adoption, emphasizing stakeholder training, system validation, and alignment with regulatory expectations. It also addresses potential barriers, such as high initial costs and resistance to technological change, offering mitigation strategies like modular implementation and pilot programs. The study concludes that MES is a pivotal technology for life sciences manufacturers, enabling robust regulatory compliance while driving operational excellence. By streamlining compliance processes, MES not only reduces the financial burden of regulatory adherence but also enhances market competitiveness through improved product quality and faster time-to-market. These findings have broader implications for the life sciences sector, suggesting that strategic MES adoption can redefine compliance as a competitive advantage rather than a regulatory burden.
Keywords: Regulatory compliance, Manufacturing Execution System (MES), cGMP, Electronic Batch Record (EBR), Life sciences, Data integrity, Compliance management systems (CMS), ISA-95, Pharmacovigilance
How to cite this article: Parapalli SL. Enhancing regulatory compliance in life sciences through MES and batch processing. Int J Drug Deliv Technol. 2026;16(6s): 362-369; DOI: 10.25258/ijddt.16.6s.38
Source of support: Nil
Conflict of interest: None